Inhibrx 提交 ozekibart 用於常規軟骨肉瘤的 BLA

Inhibrx 於 2026 年 4 月向 FDA 提交了 ozekibart 用於常規軟骨肉瘤的 BLA。該公司還計劃在 2026 年下半年與 FDA 會面，討論 CRC 一線註冊試驗以及四線 CRC 和難治性尤因肉瘤的潛在加速途徑。

關鍵事實

申報時間: 2026年4月21日下午08:04
事件: 申請已送件
方向: 中性
公司: INBXInhibrx
資產: ozekibart
來源: SEC 8-K
可信度: 有出處

來源摘錄

inhibrx-20260421 FALSE 0002007919 0002007919 2026-04-21 2026-04-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2026 INHIBRX BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-42031 99-0613523 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 11025 N. Torrey Pines Road , Suite 140 La Jolla , CA 92037 (Address of Principal Executive Offices and Zip Code) Registrant’s telephone number, including area code: ( 858 ) 795-4220 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy th

SEC 8-K